NCT02171780View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

July 31, 2005

Conditions
Healthy
Interventions
DRUG

BI 1744 CL

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02171780 - A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter